Physician profile
Shari L Sharp
NPI 1285664458
$2,446.32
in general payments reported to CMS, 2019-2025
18 companies · $480 in 2025
The $480 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $454 · 2023: $569 · 2024: $582 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.69 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $241.42 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $240.03 | 2022-2024 | Farxiga, Airsupra |
| Exact Sciences Corporation | $193.33 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $77.47 | 2021-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $69.62 | 2021-2022 | |
| Pfizer INC. | $65.29 | 2023 | |
| Seqirus USA INC | $33.51 | 2021-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Merck Sharp & Dohme LLC | $33.02 | 2022-2024 | Gardasil 9, Capvaxive, Vaxelis |
| Eisai INC. | $24.45 | 2025 | |
| Idorsia Pharmaceuticals US INC | $24.29 | 2023 | Quviviq |
| Novo Nordisk INC | $23.43 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.68 | 2021 | |
| Genzyme Corporation | $21.60 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $18.82 | 2022 | |
| Lucid Diagnostics INC. | $18.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.